Zenotech LaboratoriesBOM:532039 +3.42%73 EBITDA Margin % is 1.94% as of Mar. 2026, which is 95% below its 10-year median of 35.71. GuruFocus rates BOM:532039 with a GF Score™ of 73/100 and a GF Value™ of ₹65.19 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 954 Drug Manufacturers companies, Zenotech Laboratories ranks better than 81.13% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zenotech Laboratories EBITDA Margin % Related Terms
Zenotech Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zenotech Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532039 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenotech Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zenotech Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenotech Laboratories (BOM:532039) has a EBITDA Margin % of 1.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenotech Laboratories and its competitors. This is 95% below median its historical median of 35.71. According to the industry distribution chart, Zenotech Laboratories ranks #180 out of 954 companies in the Drug Manufacturers industry, placing it in the top 18.9%.
Is Zenotech Laboratories' EBITDA Margin % too high?
Zenotech Laboratories' current EBITDA Margin % of 1.94% is 95% below median its 10-year median of 35.71. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Zenotech Laboratories' value of 1.94% is 84.5% below this industry median. Based on the distribution chart, Zenotech Laboratories ranks #180 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zenotech Laboratories has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenotech Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenotech Laboratories ranks #180 out of 954 companies for EBITDA Margin %. This places Zenotech Laboratories in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Zenotech Laboratories' value of 1.94% is 84.5% below this benchmark. While the company's 10-year median is 35.71 vs. the industry median of 12.52, Zenotech Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenotech Laboratories's current EBITDA Margin % of 1.94% is 84.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenotech Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenotech Laboratories's current EBITDA Margin % is 1.94%, which is 95% below median its own 10-year median of 35.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenotech Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zenotech Laboratories (BOM:532039) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹65.19, compared to a current price of ₹45.91 — trading 29.6% below its estimated fair value. The current EBITDA Margin % is 1.94%, which is 95% below median its 10-year median of 35.71 and 84.5% below the Drug Manufacturers industry median of 12.52. Zenotech Laboratories' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zenotech Laboratories (BOM:532039), the current EBITDA Margin % is 1.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenotech Laboratories (BOM:532039) Overvalued in 2026?
Based on GuruFocus' analysis, Zenotech Laboratories stock appears to be undervalued.
The current stock price of ₹45.91 is trading 29.6% below its estimated GF Value™ of ₹65.19.
GuruFocus considers Zenotech Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:532039:
EBITDA Margin %: 1.94% (95% below median its 10-year median of 35.71)
GF Value™: ₹65.19 vs. price of ₹45.91 (29.6% below fair value)
Industry Position: 84.5% below the Drug Manufacturers median (#180 of 954)
No single metric tells the full story. See the BOM:532039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
73GF Score
Get the complete analysis for BOM:532039
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532039 has been successfully added to your 
